VKH
CTIC

Virtu KCG Holdings’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Virtu KCG Holdings’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$43K Sell
13,015
-738
-5% -$2.87K ﹤0.01% 2626
2017
Q1 		$58K Buy
13,753
+2,952
+27% +$13.6K ﹤0.01% 2811
2016
Q4 		$44K Buy
10,801
+7,809
+261% +$32.4K ﹤0.01% 3116
2016
Q3 		$11K Sell
2,992
-10,699
-78% -$39K ﹤0.01% 2970
2016
Q2 		$47K Buy
+13,691
New +$62.8K ﹤0.01% 2691
2016
Q1 		– Sell
-7,673
Closed -$94K – 4214
2015
Q4 		$94K Sell
7,673
-2,910
-27% -$38.8K ﹤0.01% 3011
2015
Q3 		$155K Sell
10,583
-22,966
-68% -$397K ﹤0.01% 2680
2015
Q2 		$656K Buy
33,549
+25,869
+337% +$499K 0.01% 1249
2015
Q1 		$143K Sell
7,680
-2,375
-24% -$53.5K ﹤0.01% 2549
2014
Q4 		$235K Buy
10,055
+345
+4% +$7.98K ﹤0.01% 2677
2014
Q3 		$235K Buy
9,710
+3,939
+68% +$102K ﹤0.01% 2702
2014
Q2 		$162K Buy
5,771
+755
+15% +$22.7K ﹤0.01% 3154
2014
Q1 		$170K Buy
5,016
+2,299
+85% +$78.6K ﹤0.01% 3062
2013
Q4 		$52K Buy
2,717
+336
+14% +$6.12K ﹤0.01% 3599
2013
Q3 		$39K Buy
+2,381
New +$27.6K ﹤0.01% 3542

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return

Virtu KCG Holdings's CTIC Position: Q2 2017 in Review

Virtu KCG Holdings reduced its CTI BioPharma Corp. (DE) Common Stock (CTIC) stake by 5.4% in Q2 2017, selling an estimated $2.87K and leaving 13,015 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

Virtu KCG Holdings first reported a position in CTIC in Q3 2013 and has held it in 15 quarters since. The position peaked at $656K in Q2 2015. 40 funds tracked by Wall St. Rank hold CTIC as of Q2 2017.

  • Virtu KCG Holdings held 13,015 shares of CTI BioPharma Corp. (DE) Common Stock worth $43K as of Q2 2017.
  • Virtu KCG Holdings sold 738 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2017, an estimated $2.87K.
  • CTI BioPharma Corp. (DE) Common Stock made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2626 holding.
  • Virtu KCG Holdings first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and has held it in 15 quarters since.
  • Virtu KCG Holdings's CTI BioPharma Corp. (DE) Common Stock position peaked at $656K in Q2 2015.
  • 40 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.